CGB5 and pancreatic adenocarcinoma: Our pan-cancer analysis demonstrates that aberrant CGB5 expression significantly correlates with poor prognosis across multiple cancer types, specifically in malignancies like GC and PAAD, potentially driven by genetic mutations, DNA methylation, and CNAs.